Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing tissue repair solutions for orthopedic applications. The company’s lead product is GelrinC, an off the shelf hydrogel implant made from a polyethylene glycol diacrylate and denatured fibrinogen conjugate designed to treat articular cartilage defects in the knee. GelrinC is delivered via the Stelar device, cured in place with ultraviolet light and intended to resorb over six to nine months…
Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing tissue repair solutions for orthopedic applications. The company’s lead product is GelrinC, an off the shelf hydrogel implant made from a polyethylene glycol diacrylate and denatured fibrinogen conjugate designed to treat articular cartilage defects in the knee. GelrinC is delivered via the Stelar device, cured in place with ultraviolet light and intended to resorb over six to nine months while supporting the formation of hyaline like cartilage. The product has received a CE mark in Europe and is being evaluated in an FDA sanctioned pivotal trial under an investigational device exemption for potential premarket approval in the United States.
The company has not yet recorded revenue from product sales as GelrinC remains in clinical development and regulatory review. To date Regentis Biomaterials Ltd. has financed its operations primarily through research grant funding, including approximately $2.34 million from the Israeli Innovation Authority and a European Union Horizon 2020 award. Future revenue is expected to derive from commercial sales of GelrinC following regulatory approval, from potential partnership agreements for distribution and from possible licensing of its Gelrin platform technology. The firm also anticipates milestone payments and royalties if collaborative development arrangements are reached with medical device companies.
The cartilage repair market in the United States represents an estimated annual opportunity of about 750,000 arthroscopic knee procedures valued at roughly $4 billion according to industry sources cited in the filing. Current standard of care microfracture surgery yields fibrous cartilage with symptom relief lasting on average eight to fourteen months while competing autologous cell based therapies such as Vericel Corporation’s MACI require two surgeries and cost approximately $40,000 per procedure. Allogeneic cartilage products like BioCartilage and Revaflex and the recently FDA approved Agili C implant from Smith & Nephew also compete but involve more complex implantation techniques or donor tissue considerations. Regentis Biomaterials Ltd. believes its GelrinC product offers a differentiated approach as an off the shelf, single procedure treatment that produces hyaline like cartilage at a lower cost and with a simpler surgical technique compared to existing alternatives.
The company’s customers are hospitals, orthopedic surgery centers and surgeons who perform knee cartilage repair procedures. The ultimate beneficiaries are patients suffering from articular cartilage injuries caused by acute trauma, repetitive use or degenerative conditions. Regentis Biomaterials Ltd. intends to pursue strategic partnerships with medical device distributors to facilitate commercial launch in Europe and the United States. No specific customer names are disclosed in the filing.